- Home
- HLVX vs ADAG Comparison
HLVX vs ADAG Comparison
Compare HLVX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ADAG
- Stock Information
- Founded
- HLVX 2020
- ADAG 2011
- Country
- HLVX United States
- ADAG China
- Employees
- HLVX N/A
- ADAG N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- ADAG Health Care
- Exchange
- HLVX Nasdaq
- ADAG Nasdaq
- Market Cap
- HLVX 105.2M
- ADAG 90.8M
- IPO Year
- HLVX 2022
- ADAG 2021
- Fundamental
- Price
- HLVX $2.15
- ADAG $1.99
- Analyst Decision
- HLVX Hold
- ADAG Strong Buy
- Analyst Count
- HLVX 1
- ADAG 1
- Target Price
- HLVX $2.00
- ADAG $8.00
- AVG Volume (30 Days)
- HLVX 364.7K
- ADAG 121.4K
- Earning Date
- HLVX 08-07-2025
- ADAG 08-05-2025
- Dividend Yield
- HLVX N/A
- ADAG N/A
- EPS Growth
- HLVX N/A
- ADAG N/A
- EPS
- HLVX N/A
- ADAG N/A
- Revenue
- HLVX N/A
- ADAG $103,204.00
- Revenue This Year
- HLVX N/A
- ADAG $6,488.89
- Revenue Next Year
- HLVX N/A
- ADAG $57.50
- P/E Ratio
- HLVX N/A
- ADAG N/A
- Revenue Growth
- HLVX N/A
- ADAG N/A
- 52 Week Low
- HLVX $1.34
- ADAG $1.33
- 52 Week High
- HLVX $2.17
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- HLVX 61.80
- ADAG 55.18
- Support Level
- HLVX $2.07
- ADAG $1.60
- Resistance Level
- HLVX $2.16
- ADAG $1.96
- Average True Range (ATR)
- HLVX 0.07
- ADAG 0.17
- MACD
- HLVX -0.00
- ADAG 0.01
- Stochastic Oscillator
- HLVX 89.47
- ADAG 84.78
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.